Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Wada, Akihisa; Enokida, Tomohiro; Okano, Susumu; Sato, Masanobu; Tanaka, Hideki; Ueda, Yoshio; Fujisawa, Takao; Takeshita, Naohiro; Tanaka, Nobukazu; Tahara, Makoto

doi:10.1016/j.ejca.2023.02.011

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 8 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported OFS, PFS2, PFS3, and OS were 3.2, 8.1, 14.0, and 17.2 months, respectively, in Japanese head and neck cancer patients receiving Nivolumab. 16 PFS2 for pembrolizumab + FP and cetuximab + FP in the KEYNOTE-048 study was 11.7 vs. 9.4 and 9.4 vs. 8.9 for CPS≥20 and CPS≥1, respectively. PFS2 for pembrolizumab alone and cetuximab + FP was 11.3 vs. 9.8 and 10.3 vs. 9.0 for CPS ≥20 and CPS ≥1, respectively.…”

Section: Discussionmentioning

confidence: 92%

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

Otsuru,

Yamakawa,

Kirita

et al. 2024

Journal of Dental Sciences

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 92%

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

Otsuru,

Yamakawa,

Kirita

et al. 2024

Journal of Dental Sciences

View full text Add to dashboard Cite

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Kang,

Liu,

Yuan

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Introduction: Tumor immunotherapy has recently emerged as a crucial focal point in oncology treatment research. Among tumor immunotherapy approaches, tumor immune checkpoint inhibitors (ICIs) have attracted substantial attention in clinical research. However, this treatment modality has bene tted only a limited number of patients. We conducted a meta-analysis of various biomarkers to decipher their prognostic implications in patients with head and neck squamous cell carcinoma (HNSCC) who are treated with ICIs and thus identify predictive markers with practical clinical relevance.Methods: A systematic search of electronic databases was conducted to identify clinical studies that examined the correlation between biomarkers and treatment outcomes in the HNSCC patients. The included articles were screened and analyzed to extract data regarding overall survival (OS), progression-free survival (PFS).Results: The relationship between the biomarkers included in the summary and prognosis was as follows: HPV positivity was associated with improved OS (

show abstract

Nivolumab

2023

Reactions Weekly

View full text Add to dashboard Cite

Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Cited by 8 publications

References 23 publications

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Nivolumab

Contact Info

Product

Resources

About